FGI-103
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | 907169-69-1 |
PubChem (CID) | 5477931 |
ChemSpider | 4585571 |
Chemical and physical data | |
Formula | C19H16N6O |
Molar mass | 344.369 |
3D model (Jmol) | Interactive image |
| |
|
FGI-103 is an antiviral drug developed as a potential treatment for the filoviruses Ebola virus and Marburg virus. In tests on mice FGI-103 was effective against both Ebola and Marburg viruses when administered up to 48 hours after infection. The mechanism of action of FGI-103 has however not yet been established, as it was found not to be acting by any of the known mechanisms used by similar antiviral drugs.[1][2][3]
See also
References
- ↑ Warren, T. K.; Warfield, K. L.; Wells, J.; Enterlein, S.; Smith, M.; Ruthel, G.; Yunus, A. S.; Kinch, M. S.; Goldblatt, M.; Aman, M. J.; Bavari, S. (2010). "Antiviral Activity of a Small-Molecule Inhibitor of Filovirus Infection". Antimicrobial Agents and Chemotherapy. 54 (5): 2152–9. doi:10.1128/AAC.01315-09. PMC 2863630. PMID 20211898.
- ↑ Bradfute, S. B.; Warfield, K. L.; Bray, M. (2012). "Mouse Models for Filovirus Infections". Viruses. 4 (12): 1477–1508. doi:10.3390/v4091477.
- ↑ De Clercq E. Ebola virus (EBOV) infection: Therapeutic strategies. Biochemical Pharmacology 1 January 2015, 93(1):1–10. doi:10.1016/j.bcp.2014.11.008
This article is issued from Wikipedia - version of the 8/8/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.